Al-Bahrani Ali I, Bayoumi Riad, Al-Yahyaee Said A
Department of Biochemistry, College of Medicine and Health Sciences Sultan Qaboos University. P.O. Box 35, Al-Khoud 123, Sultanate of Oman.
Sultan Qaboos Univ Med J. 2006 Dec;6(2):19-25.
To evaluate the impact of the National Cholesterol Educational Program Adult Treatment Panel III (ATP III) and the Framingham Offspring Study on Omani diabetic subjects.
221 subjects with type 2 diabetes (86 females and 135 males) and 156 non-diabetic subjects (70 females and 86 males) aged 30-70 years attending Sultan Qaboos University Hospital between 1999-2002 were recruited. Lipid profile, glucose, %HbA(1c), apoproteinA-1 and apoproteinB were measured. Low density lipoprotein was calculated using the Friedwald formula. ATP-III and Framingham Offspring Study guidelines were used to classify lipid parameters into coronary heart disease-risk categories.
Diabetic compared to non-diabetic subjects had significantly higher triglycerides of >1.7 mmol/L (p=0.01) and lower low density lipoprotein cholesterol of >4.2 mmol/L (p=0.012) and, in female subjects only, lower high density lipoprotein cholesterol of <1.15 mmo/L for (p<0.0001). In addition, 57% of diabetic subjects had abnormal aplipoproteinB of >1.2 g/L compared to 49% of non-diabetic subjects. Combined raised levels of triglycerides, apolipoproteinB and low levels of high density lipoprotein were found in 42% of diabetic compared to 26% of the non-diabetic subjects (p=0.05). Diabetic subjects had significantly higher (p=0.008) NCEP risk-score for coronary artery disease, however, only 34% conformed to a NCEP 10-year-risk score of >10%.
A substantial proportion of the Omani diabetic subjects were dyslipidaemic according to the ATP III guidelines. This study recommends the implementation of a lower cut-off threshold for starting lipid-modifying agents for Omani diabetics when using the 10-year Framingham Risk Scoring equation.
评估美国国家胆固醇教育计划成人治疗组第三次报告(ATP III)和弗雷明汉后代研究对阿曼糖尿病患者的影响。
招募了1999年至2002年间在苏丹卡布斯大学医院就诊的221名年龄在30至70岁之间的2型糖尿病患者(86名女性和135名男性)以及156名非糖尿病患者(70名女性和86名男性)。测量了血脂谱、血糖、糖化血红蛋白百分比、载脂蛋白A-1和载脂蛋白B。使用弗里德瓦尔德公式计算低密度脂蛋白。采用ATP-III和弗雷明汉后代研究指南将血脂参数分类为冠心病风险类别。
与非糖尿病患者相比,糖尿病患者的甘油三酯显著更高,>1.7 mmol/L(p = 0.01),低密度脂蛋白胆固醇显著更低,>4.2 mmol/L(p = 0.012),并且仅在女性患者中,高密度脂蛋白胆固醇显著更低,<1.15 mmol/L(p < 0.0001)。此外,57%的糖尿病患者载脂蛋白B异常,>1.2 g/L,相比之下,非糖尿病患者为49%。42%的糖尿病患者甘油三酯、载脂蛋白B水平升高且高密度脂蛋白水平降低,相比之下,非糖尿病患者为26%(p = 0.05)。糖尿病患者的冠心病NCEP风险评分显著更高(p = 0.008),然而,只有34%的患者符合NCEP 10年风险评分>10%。
根据ATP III指南,很大一部分阿曼糖尿病患者存在血脂异常。本研究建议在使用10年弗雷明汉风险评分方程时,为阿曼糖尿病患者启动降脂药物设定更低的临界阈值。